Peptide News Digest

#Interlude-Biopharma

1 story

Clinical Trials · View digest

Interlude Biopharma Plans a 414-Person Phase 3 Trial Testing Whether the Oral Peptide Larazotide Can Prevent Gluten Damage in Celiac Disease

Miami-based Interlude Biopharma said November 19 that it will start a U.S. Phase 3 trial of larazotide acetate, an oral peptide that blocks zonulin to keep the seals between gut-lining cells closed, in the first quarter of 2027. About 414 people aged 12 to 80 with biopsy-confirmed, well-controlled celiac disease will take 0.25 mg or 0.5 mg three times daily, or placebo, for 14 weeks while eating study bars with 500 mg of gluten, first every other day and then daily. The main goal is the share of patients whose intestinal lining and symptoms stay stable. A 342-patient Phase 2b trial met its symptom goal at the 0.5 mg dose, but an earlier Phase 3 trial run by 9 Meters Biopharma was stopped in 2022 after an interim analysis showed it would need too many more patients.